+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
MyoKardia Inc - logo

MyoKardia is a clinical stage biopharmaceutical company that develops therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, a small molecule that is in three Phase I clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

From
Cardiovascular Collaboration and Licensing Deals 2016-2024 - Product Thumbnail Image

Cardiovascular Collaboration and Licensing Deals 2016-2024

  • Report
  • October 2024
  • 300 Pages
  • Global
From
From
From
Dilated Cardiomyopathy - Pipeline Insight, 2024 - Product Thumbnail Image

Dilated Cardiomyopathy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Collaboration Deals in Pharmaceuticals 2019-2024 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2019-2024

  • Report
  • September 2024
  • 1150 Pages
  • Global
From
Licensing Deals in Pharmaceuticals 2019-2024 - Product Thumbnail Image

Licensing Deals in Pharmaceuticals 2019-2024

  • Report
  • September 2024
  • 1400 Pages
  • Global
From
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2020 - Product Thumbnail Image

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 631 Pages
  • Global
From
  • 11 Results (Page 1 of 1)
Loading Indicator